IMS R&D Focus – sample record continued…
{"Image DocumentName": "IMS R&D Focus \u2013 sample record continued\u2026", "Image ImageDescription": "LATEST INFORMATION: 27 September 2004: At the European Partnering & Investment Conference, 16 September 2004, London, UK, R&D focus discussed PowderMed s proprietary Powder Mediated Epidermal Delivery (PMED) technology with Clive Dix, CEO of PowderMed, and Brenda Reynolds, COO. The PMED technology has utility in the development of therapeutic DNA vaccines, and PowderMed is seeking partners interested in collaborations using the PMED technology. The technology uses the PowderJect device to propel DNA precipitated onto microscopic gold particles into the epidermis. Microscopic gold particles, 1-3 mcM in diameter, have an appropriate density and size for direct DNA delivery into immunological active antigen presenting cells (APC). Once inside the APC, the DNA elutes off the gold and produces the encoded protein; the presentation of this protein by the APC to the lymphocytes results in the generation of T-cell-mediated immune responses. The technology can be used to develop vaccines that generate T-cell mediated responses to a broad range of viral and cancer antigens\u2026.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}